The NCI-MATCH trial: lessons for precision oncology

被引：60

作者：

O'Dwyer, Peter J. ^{[1
]}

Gray, Robert J. ^{[2
]}

Flaherty, Keith T. ^{[3
]}

Chen, Alice P. ^{[4
]}

Li, Shuli ^{[2
]}

Wang, Victoria ^{[2
]}

McShane, Lisa M. ^{[5
]}

Patton, David R. ^{[6
]}

Tricoli, James V. ^{[4
]}

Williams, P. Mickey ^{[7
]}

Iafrate, A. John ^{[3
]}

Sklar, Jeffrey ^{[8
]}

Mitchell, Edith P. ^{[9
]}

Takebe, Naoko ^{[4
]}

Sims, David J. ^{[7
]}

Coffey, Brent ^{[6
]}

Fu, Tony ^{[7
]}

Routbort, Mark ^{[10
]}

Rubinstein, Larry V. ^{[5
]}

Little, Richard F. ^{[4
]}

Arteaga, Carlos L. ^{[11
]}

Marinucci, Donna ^{[12
]}

Hamilton, Stanley R. ^{[13
]}

Conley, Barbara A. ^{[14
]}

Harris, Lyndsay N. ^{[14
]}

Doroshow, James H. ^{[4
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] ECOG ACRIN Biostat Ctr, Dana Farber Canc Inst, Boston, MA USA

[3] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[4] NCI, Div Canc Treatment & Diag, Bethesda, MD USA

[5] NCI, Biometr Res Program, Div Canc Treatment & Diag, Bethesda, MD USA

[6] NCI, Ctr Biomed Informat & Informat Technol, Bethesda, MD USA

[7] Frederick Natl Lab Canc Res, Frederick, MD USA

[8] Yale Univ, New Haven, CT USA

[9] Thomas Jefferson Univ Hosp, Philadelphia, PA USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[11] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[12] ECOG ACRIN Canc Res Grp, Philadelphia, PA USA

[13] City Hope Natl Med Ctr, Duarte, CA USA

[14] NCI, Canc Diag Program, Div Canc Treatment & Diag, Bethesda, MD USA

来源：

NATURE MEDICINE | 2023年 / 29卷 / 6期

关键词：

PHASE-II; SOLID TUMORS; CANCERS; BRAF; VEMURAFENIB; INHIBITION; VALIDATION; TRAMETINIB; MUTATIONS; THERAPY;

D O I：

10.1038/s41591-023-02379-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The NCI-MATCH (Molecular Analysis for Therapy Choice) trial () was launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial-largely for patients with treatment-refractory, malignant solid tumors. Having completed in 2023, it remains one of the largest tumor-agnostic, precision oncology trials undertaken to date. Nearly 6,000 patients underwent screening and molecular testing, with a total of 1,593 patients (inclusive of continued accrual from standard next-generation sequencing) being assigned to one of 38 substudies. Each substudy was a phase 2 trial of a therapy matched to a genomic alteration, with a primary endpoint of objective tumor response by RECIST criteria. In this Perspective, we summarize the outcomes of the initial 27 substudies in NCI-MATCH, which met its signal-seeking objective with 7/27 positive substudies (25.9%). We discuss key aspects of the design and operational conduct of the trial, highlighting important lessons for future precision medicine studies.

引用

页码：1349 / 1357

页数：9

共 50 条

[31] Clinical tumour sequencing for precision oncology: time for a universal strategy
Cheng, Michael L.
Berger, Michael F.
Hyman, David M.
Solit, David B.
NATURE REVIEWS CANCER, 2018, 18 (09) : 527 - 528
[32] Current Opportunities and Future Vision of Precision Medicine in Radiation Oncology
Kirsch, David G.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : 267 - 270
[33] Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Krop, Ian E.
Jegede, Opeyemi A.
Grilley-Olson, Juneko E.
Lauring, Josh D.
Mitchell, Edith P.
Zwiebel, James A.
Gray, Robert J.
Wang, Victoria
McShane, Lisa M.
Rubinstein, Larry, V
Patton, David
Williams, P. Mickey
Hamilton, Stanley R.
Kono, Scott A.
Ford, James M.
Garcia, Agustin A.
Sui, Xingwei D.
Siegel, Robert D.
Slomovitz, Brian M.
Conley, Barbara A.
Arteaga, Carlos L.
Harris, Lyndsay N.
O'Dwyer, Peter J.
Chen, Alice P.
Flaherty, Keith T.
JCO PRECISION ONCOLOGY, 2022, 6
[34] Attrition of Patients on a Precision Oncology Trial: Analysis of theI-PREDICTExperience
Bohan, Sandy S.
Sicklick, Jason K.
Kato, Shumei
Okamura, Ryosuke
Miller, Vincent A.
Leyland-Jones, Brian
Lippman, Scott M.
Kurzrock, Razelle
ONCOLOGIST, 2020, 25 (11) : E1803 - E1806
[35] Precision Oncology in Gastrointestinal Stromal Tumors
Mechahougui, Hiba
Michael, Montemurro
Friedlaender, Alex
CURRENT ONCOLOGY, 2023, 30 (05) : 4648 - 4662
[36] Progress in precision therapy in pediatric oncology
O'Donohue, Tara
Sait, Sameer Farouk
Bender, Julia Glade
CURRENT OPINION IN PEDIATRICS, 2023, 35 (01) : 41 - 47
[37] A systematic analysis of the landscape of synthetic lethality-driven precision oncology
Schaffer, Alejandro A.
Chung, Youngmin
Kammula, Ashwin, V
Ruppin, Eytan
Lee, Joo Sang
MED, 2024, 5 (01): : 73 - 89
[38] Importance of genetic screens in precision oncology
Mulero-Sanchez, Antonio
Pogacar, Ziva
Vecchione, Loredana
ESMO OPEN, 2019, 4 (03)
[39] Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study
Zivanovic Bujak, Andjelija
Weng, Chen-Fang
Silva, Maria Joao
Yeung, Miriam
Lo, Louisa
Ftouni, Sarah
Litchfield, Cassandra
Ko, Yi-An
Kuykhoven, Keilly
Van Geelen, Courtney
Chandrashekar, Sushma
Dawson, Mark A.
Loi, Sherene
Wong, Stephen Q.
Dawson, Sarah-Jane
PLOS MEDICINE, 2020, 17 (10)
[40] The coming decade in precision oncology: six riddles
Wahida, Adam
Buschhorn, Lars
Frohling, Stefan
Jost, Philipp J.
Schneeweiss, Andreas
Lichter, Peter
Kurzrock, Razelle
NATURE REVIEWS CANCER, 2023, 23 (01) : 43 - 54

← 1 2 3 4 5 →